, Volume 5, Issue 4, pp 343–350

Drug Prices and Third Party Payment

Do They Influence Medication Selection?
  • Janet E. Hux
  • C. David Naylor
Original Research Article


The growing burden of prescription drug costs has focused attention on factors which influence physicians’ prescribing decisions. We hypothesised that third party coverage of prescription costs would elicit selection of expensive drugs, but that this tendency could be moderated by price reminders.

In a mailed survey, primary care physicians throughout Ontario (n = 1072) were provided with the clinical scenario of a patient with an infectious exacerbation of chronic obstructive pulmonary disease, and asked to select diagnostic tests as well as 1 of 6 antibiotics. Two antibiotics were expensive (ciprolloxacin and cefaclor; average price $Can52.23). and 4 inexpensive [amoxicillin. couimoxazole (trimethoprim/sulfamethoxazole), erythromycin and tetracycline; average price $Can2.80]. Neither expensive drug is considered first line therapy for the condition described. Questionnaires differed in the presence or absence of drug benefit coverage and price information.

The response rate was 71 %. With third party cost coverage and prices shown, 18% of respondents selected an expensive antibiotic. This increased to 38% when the prices were omitted [odds ratio 2.72; 95% confidence interval (CI) 1.61, 4.60; p < 0.001], and decreased to 8% when the patient was said to have no drug benefits coverage (odds ratio 0.40; 95% CI 0.19, 0.84; p < 0.01). On a control questionnaire in which neither cost coverage nor prices were specified. and in which respondents were asked to indicate the most appropriate antibiotic, 37% selected an expensive drug (relative to the version giving both prices and cost coverage: odds ratio 2.70; 95% CI 1.62, 4.53; P < 0.001).

We conclude that inappropriate selection of expensive antibiotics is increased when the patient has full drug benefit coverage but reduced when physicians are reminded of drug prices. These results support assessment of a price-oriented educational intervention in an effort to reduce inappropriately expensive prescribing.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behaviour of physicians. American Journal of Medicine 73: 4–8, 1982PubMedCrossRefGoogle Scholar
  2. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based ‘detailing’. New England Journal of Medicine 308: 1457–1463, 1983PubMedCrossRefGoogle Scholar
  3. Brody B, Wray N, Bame S, Ashton C, Petersen N, et al. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy. Medical Care 29: 899–910, 1991PubMedCrossRefGoogle Scholar
  4. Canadian Medical Directory. Don Mills, Soulham Business Communications Inc., 1991Google Scholar
  5. Caudill TS, Rich EC, Johnson MMS, McKirmey PW. Physicians, pharmaceutical representatives, and the cost of prescribing. Abstract. Clinical Research 40: 811A, 1992Google Scholar
  6. Connelly DP, Rich EC, Curley SP, Kelly JT. Knowledge resource preferences of family physicians. Journal of Family Practice 30: 353–359, 1990PubMedGoogle Scholar
  7. Drug Quality and Therapeutics Committee. Drug Quality and Therapeutics Committee Bulletin 1, 1992Google Scholar
  8. Editorial, Antibiotics for exacerbations of chronic bronchitis? Lancet 2: 23–24, 1987Google Scholar
  9. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Annals of Internal Medicine 115: 116–121, 1991PubMedGoogle Scholar
  10. Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. Journal of the American Medical Association 264: 1438–1440, 1990PubMedCrossRefGoogle Scholar
  11. Hall CB, Douglas RG. Influenza and infections of the trachea, bronchi and bronchioles. In Reese & Betts (Eds) A practical approach to infectious diseases, 3rd ed., pp. 184–198, Little Brown and Company, Boston, 1991Google Scholar
  12. Harris BL, Stergachis A, Ried LD. The effect of drug copayments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care 28: 907–917, 1990PubMedCrossRefGoogle Scholar
  13. Johnson RE, Mollis JF, Stevens VJ, Woodson GT. Patterns of nicotine gum use in a health maintenance organization. DICP: Annals of Pharmacotherapy 25: 730–735, 1991PubMedGoogle Scholar
  14. Kozma CM, Reeder CE, Lingle EW. Expanding medicaid drug formulary coverage: effects on utilization of related sevices. Medical Care 28: 963–977, 1990PubMedCrossRefGoogle Scholar
  15. Lessler DS, Avins AL. Cost, uncertainty and doctors’ decisions: the case of thrombolytic therapy. Archives of Internal Medicine 152: 1665–1672, 1992PubMedCrossRefGoogle Scholar
  16. Newton-Syms FA, Dawson PH, Cooke J, Feely M, Booth TG, et al. The influence of an academic representative on prescribing by general practitioners. British Journal of Clinical Pharmacology 33: 69–73, 1992PubMedCrossRefGoogle Scholar
  17. Ontario Ministry of Health. Drug benfit formulary/comparative drug index, Publications Ontario, Toronto, 1992Google Scholar
  18. Orlowski JP, Wateska L. The effect of pharmaceutical firm enticements on physician prescribing patterns: there’s no such thing as a free lunch. Chest 102: 270–273, 1992PubMedCrossRefGoogle Scholar
  19. Pedersen SS. Clinical efficacy of ciprofloxacin in lower respiratory tract infections. Scandanavian Journal of Infectious Diseases 60(Suppl.): 89–97, 1989Google Scholar
  20. Rodnick JE, Gude JK. The use of antibiotics in acute bronchitis and acute exacerbations of chronic bronchitis. Western Journal of Medicine 149: 347–351, 1988PubMedGoogle Scholar
  21. Safavi KT, Hayward RA. Choosing between apples and apples: physicians’ choices of prescription drugs that have similar side effects and efficacies. Journal of General Internal Medicine 7: 32–37, 1992PubMedCrossRefGoogle Scholar
  22. Soumerai SB, Avorn J. Economic and policy analysis of university-based drug ‘detailing’. Medical Care 24: 313–331, 1986PubMedCrossRefGoogle Scholar
  23. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under medicaid: effects on therapy, cost, and equity. New England Journal of Medicine 317: 550–556, 1987PubMedCrossRefGoogle Scholar
  24. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine 325: 1072–1077, 1991PubMedCrossRefGoogle Scholar
  25. Steele MA, Bess DT, Franze VL, Graber SE. Cost-effectiveness of two interventions for reducing outpatient prescribing costs. DICP 23: 497–500, 1989PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Janet E. Hux
    • 1
  • C. David Naylor
    • 2
    • 3
  1. 1.Clinical Epidemiology Unit, and Department of Medicine Postgraduate ProgramUniversity of TorontoTorontoCanada
  2. 2.Division of General Internal Medicine, and The Institute for Clinical Evaluative SciencesSunnybrook Health Science CentreNorth YorkCanada
  3. 3.Departments of Medicine, Surgery. and Health AdministrationUniversity of TorontoTorontoCanada

Personalised recommendations